Peter Welford
Stock Analyst at Jefferies
(2.45)
# 2,474
Out of 5,012 analysts
13
Total ratings
80%
Success rate
8.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Welford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK plc | Downgrades: Hold | n/a | $43.50 | - | 3 | Nov 12, 2024 | |
| NVS Novartis AG | Downgrades: Hold | n/a | $131.55 | - | 2 | Sep 3, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $85.87 | - | 4 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $34.93 | +35.13% | 3 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $32.64 | - | 1 | Sep 16, 2021 |
GSK plc
Nov 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $43.50
Upside: -
Novartis AG
Sep 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $131.55
Upside: -
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $85.87
Upside: -
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $34.93
Upside: +35.13%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $32.64
Upside: -